NCT03169985View on ClinicalTrials.gov

Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

July 12, 2017

Primary Completion Date

January 28, 2027

Study Completion Date

January 28, 2027

Conditions
Coronary Artery Disease
Interventions
DRUG

Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day

After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.

DRUG

Rosuvastatin 20 mg orally once a day

After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.

Trial Locations (1)

06351

Samsung Medical Center, Seoul

Sponsors
All Listed Sponsors
collaborator

Hanmi Pharmaceutical co., ltd.

OTHER

lead

Samsung Medical Center

OTHER